Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559891 · ClinicalTrials.gov registry record · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
A NA study of Hypertension, sponsored by SoniVie.
- Recruiting
- Registry status
- NA
- Development phase
- 261
- Enrollment target
- 20
- Study locations
NCT06559891: Recruiting NA study of Hypertension, sponsored by SoniVie.
NCT06559891 is a NA study of Hypertension that is actively recruiting participants, run by SoniVie. The registered enrollment target is 261 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06559891, a NA study of Hypertension, is actively recruiting participants, sponsored by SoniVie.
- RECRUITING
- Registry status
- NA
- Development phase
- 261 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with hypertension (HTN) receiving up to 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving up to 2 anti-hypertensive drugs of different classes and who accept to be off-medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after the procedure
Primary Outcome
Primary outcome
Conditions Studied
Interventions
- OTHER Sham
- DEVICE TIVUS™ Renal Denervation System
Study Locations (20)
Illinois
- Ascension Alexian Brothers - Elk Grove Village
- St. John's Prairie Heart - Springfield
- Southern Illinois University, School of Medicine - Springfield
Arkansas
- St. Bernard's Medical Center - Jonesboro
- Arkansas Heart Hospital - Little Rock
California
- Cedar-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Florida
- Ascension- Sacred Heart - Pensecola
- University of South Florida - Tampa
Louisiana
- Cardiovascular Institute of the South - Houma
- Ochsner Medical Center - New Orleans
Michigan
- Henry Ford Hospital - Detroit
- Henry Ford Providence Hospital - Southfield
Mississippi
- Gulfport Memorial Hospital - Gulfport
- Jackson Heart - Jackson
Missouri
- St. Luke's Hospital - Kansas City
- St Lukes Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2024-10-03 |
| Est. Completion | 2028-08-15 |
| Phase | NA |
What NCT06559891 shows while recruiting
NCT06559891 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT06559891 names 20 study sites across 11 states, led by Illinois, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT06559891 about?
NCT06559891 is a clinical study titled "THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension". The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with hypertension (HTN) receiving up to 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a ...
What is the current status of trial NCT06559891?
This trial is currently recruiting. It is a NA study. The enrollment target is 261 participants. The study started on 2024-10-03. Estimated completion is 2028-08-15.
What conditions does trial NCT06559891 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06559891?
The interventions under investigation include: Sham (OTHER), TIVUS™ Renal Denervation System (DEVICE).
Who is sponsoring clinical trial NCT06559891?
This trial is sponsored by SoniVie, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559891 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06559891's enrollment target sits among peer trials
261 190th of 470 higher than 281 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
- NCT06293703 · 262 participants · NA
Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI